Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

October 30, 2006 08:01 ET

Ambrilia to Present at the Rodman & Renshaw 8th Annual Healthcare Conference in New-York

MONTREAL, QUEBEC--(CCNMatthews - Oct. 30, 2006) - Ambrilia Biopharma Inc.(TSX:AMB), a biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases, announced today that it's President and Chief Executive Officer, Hans J. Mader, will present an overview of the Company's latest developments at the Rodman & Renshaw 8th Annual Healthcare Conference to be held in New-York, November 6-8. This presentation will take place on Monday, November 6, at 9:10 a.m. local time, in Kennedy I room.

Surrounding the presentation, Ambrilia's Management will conduct 1X1 meetings with U.S. institutions at the conference and in the New York City area.


Ambrilia Biopharma Inc.(TSX:AMB) is a biopharmaceutical company developing innovative and proprietary early- to mid-stage therapeutics in the fields of oncology and infectious diseases. Ambrilia's product portfolio includes an anti-cancer therapeutic peptide (PCK3145), a novel anti-cancer therapy (TVT-Dox), two oncology specialty generics (Octreotide, Goserelin), the first of which is late-stage and value-added, and promising anti-HIV treatments (PPL-100, Anti-HIV Peptides, Integrase Inhibitor Program). Exclusive worldwide rights to PPL-100 and its related compounds have been granted to Merck & Co., Inc. in return for milestone payments that could total up to $US 232 million. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site:

Ambrilia's forward-looking statements

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company's filings. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia's products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia's views to change, Ambrilia specifically disclaims any obligation to update these forward-looking statements.

Contact Information